Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS

Intervention/treatment:
REGN668 (DUPILUMAB)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
R668-AD-1225
Control number:
171383
Status:
Closed
Approved:
February 13, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT01949311
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Trials Administrator
Organization
Regeneron Pharmaceuticals, Inc.
Phone:
1-844-734-6643
Sponsor
REGENERON PHARMACEUTICALS INC

Locations

Alberta

Regeneron Study Site 1
Calgary, Alberta
Regeneron Study Site 1
Edmonton, Alberta
Regeneron Study Site 2
Calgary, Alberta
Regeneron Study Site 2
Edmonton, Alberta

British Columbia

Regeneron Study Site
Winnipeg, British Columbia
Regeneron Study Site 1
Surrey, British Columbia
Regeneron Study Site 1
Vancouver, British Columbia
Regeneron Study Site 2
Surrey, British Columbia
Regeneron Study Site 2
Vancouver, British Columbia
Regeneron Study Site 3
Vancouver, British Columbia

Manitoba

Regeneron Study Site
Ste-Foy, Manitoba
Regeneron Study Site 1
Winnipeg, Manitoba

New Brunswick

Regeneron Study Site
Bathurst, New Brunswick

Newfoundland and Labrador

Regeneron Study Site
St. John's, Newfoundland and Labrador

Ontario

Regeneron Study Site
Ajax, Ontario
Regeneron Study Site
Etobicoke, Ontario
Regeneron Study Site
Markham, Ontario
Regeneron Study Site
Mississauga, Ontario
Regeneron Study Site
Newmarket, Ontario
Regeneron Study Site
North Bay, Ontario
Regeneron Study Site
Oakville, Ontario
Regeneron Study Site
Peterborough, Ontario
Regeneron Study Site
Toronto, Ontario
Regeneron Study Site
Waterloo, Ontario
Regeneron Study Site 1
Barrie, Ontario
Regeneron Study Site 1
Hamilton, Ontario
Regeneron Study Site 1
Ottawa, Ontario
Regeneron Study Site 1
Richmond Hill, Ontario
Regeneron Study Site 1
Windsor, Ontario
Regeneron Study Site 2
Barrie, Ontario
Regeneron Study Site 2
Hamilton, Ontario
Regeneron Study Site 2
Richmond Hill, Ontario
Regeneron Study Site 2
Windsor, Ontario

Quebec

Regeneron Study Site
Drummondville, Quebec
Regeneron Study Site
Montreal, Quebec
Regeneron Study Site 3
Ste-Foy, Quebec

Results

See the results from the trial NCT01949311. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?